BioSante Pharmaceuticals, Inc., founded in 1996 and headquartered in the suburbs of Chicago, Illinois, licenses and develops hormone therapy products, focusing on transdermal gels that deliver bioidentical estradiol and testosterone to treat men and women. Its lead products were Elestrin, an FDA-approved gel for menopausal symptoms in women, marketed in the U.S. by Bradley Pharmaceuticals, and LibiGel, a gel for female sexual dysfunction in Phase III trials. Other products in development included Bio-E/P-Gel, LibiGel-E/T, Bio-T-Gel for testosterone deficiency in men, and triple hormone contraceptives.
The company also develops its proprietary calcium phosphate nanotechnology (CaP), mainly for vaccine adjuvants, immune system boosters and drug delivery. Its lead CaP product, BioVant, was being applied to hepatitis B, avian flu and biodefense vaccines, and other CaP products include BioOral, BioAir and BioCap for aesthetic medicine. In June 2007 BioSante completed an $18.3 million private placement.
AMEX: BPA · Pharmaceuticals
Read the corporate profile (PDF, 1 pages)
Since then: Acquired by ANI Pharmaceuticals.